Oncotelic Therapeutics says contractor Cromos Pharma will conduct the registrational trial for its pancreatic cancer drug candidate, OT101.
The contract – which was announced late last week – will see the US CRO run the study on behalf of its joint venture partner, GMP Biotechnology Limited's wholly owned subsidiary - Sapu Bioscience.
The study will compare OT101 – a TGF-β2 Targeting antisense oligonucleotide – in combination with Folfirinox with Folfirinox Alone in patients with advanced and unresectable or metastatic pancreatic Cancer.
Oncotelic said Sapu has engaged Cromos “to assist in the conduct of the trial. Leveraging Cromos Pharma's distinguished oncological expertise, this collaboration underscores the joint commitment to bring innovative treatments to cancer patients.”
The firm also cited Cromos “renowned proficiency in site selection, and its vast global network for patient enrolment, stands as an invaluable asset for this clinical trial venture.”
“Handling complex trials with precision, Cromos Pharma's unparalleled expertise should ensure efficient, high-quality site choices and good global patient onboarding. For a trial of such magnitude and intricacy, Cromos Pharma's involvement is pivotal and will ensure streamlined operations and meticulous execution that can potentially hasten the time towards finding a solution for this devastating cancer.”
According to current statistics rates of pancreatic cancer are rising-and are rising faster among younger women, particularly black women, than among men of the same age. Pancreatic cancer has the highest mortality rate of all major cancers, accounting for 3% of all cancer deaths in the US, and is more common among men than women.
Cromos CEO Vlad Bogin said “It's truly an honour for Cromos to collaborate with Sapu and Oncotelic, visionaries within the oncology space. With over 20 years in the drug development cycle I have witnessed first-hand the monumental impact such partnerships can have on advancing medicine.
“Our expertise will ensure that this clinical trial's complexities are navigated with precision and efficiency. Together, we aim to break new ground to bring a new therapy to those affected by pancreatic cancer.”